Now that Johnson & Johnson has joined Pfizer and Moderna in having a COVID-19 vaccine authorized in the U.S., the question on many people's minds is: who gets which vaccine?

Much of the discussion has focused on the differing vaccine efficacy numbers for the three products: those given for the J&J vaccine are in the 70% range, versus more than 90% for Pfizer's and Moderna's.

In this MedPage Today story, Professor Chris Martin, MD, discusses targeted vaccine distribution and efficacy. (Downloadable PDF available here.) 

Additional coverage: